Pharma & Biotech Patent Litigation Summit (& UPC Litigation Forum) returns to Amsterdam with 15% IPKat readers’ discount
 |
| A stroll along the Amsterdam canals is a must |
The full event agenda is available here.
According to the organizers, this is Europe’s premier event for patent litigation professionals. Over 450 industry experts are expected to gather for a deep dive deep into the most pressing challenges and innovations in contentious IP law. The latest case law, regulatory updates, and strategic litigation approaches will all be covered, while participants will connect with key stakeholders who drive the future of life sciences IP.
New to this year is the inaugural Diversity & Inclusion in IP workshop during the conference's UPC Litigation Forum, featuring targeted workshop discussions.
The 2025 edition’s highlights include:
- Latest life science litigation, including cross-border cases, biosimilars, vaccines, and SPCs.
- The UPC’s impact on the life sciences sector, featuring industry-focused panels and a pre-event forum for practical, cross-industry discussions.
- Targeted, in-depth discussions with tracked sessions on MedTech, Large Molecule, and Small Molecule patent litigation.
- Key updates and challenges in divisional patenting, PIs, second medical use, G2/21, and the Bolar exemption from top pharma and biotech IP specialists.
- Judicial perspectives from top UPC technical and legal judges and within the Global Judges Panel session.
IPKat readers are entitled to a 15% discount in the registration fee using VIP code IPKAT_SM at checkout. For further information and to register, click here.
Pharma & Biotech Patent Litigation Summit (& UPC Litigation Forum) returns to Amsterdam with 15% IPKat readers’ discount
Reviewed by Eleonora Rosati
on
Wednesday, September 25, 2024
Rating:
Reviewed by Eleonora Rosati
on
Wednesday, September 25, 2024
Rating:
Follow the IPKat on LinkedIn ![[Event Report] #2 Digital Knowledge – The Library and Copyright in a Global Digital Economy](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg8ltuL9Ic8Y359PW7QNt2BvZLt5zKwlYx06zE3rTh5AaP_J3D5IoqQoGQRsQJDp4P0UUPdXHGae-Vx_sMu1czZg3y__o2ffUAXQWDDhjxnPDsH4XlKA478QWShAJ6lg8kLiqv0uNuuFNnzVg8SQGOQcjWQmkU5fPghAMdCJ5AlY0k3LGg7ZQ/s72-c/20240913_135242.jpg)
![[GuestPost] The Court of Appeal's latest AI decision begs the question - what inventions are deserving of patent protection?](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhA7tPmh6FacHeANUNGfp6c1UUhYHOu0ocD2vMSa844NtpY_Y3UCbJp9LNBt_qKMhNG6pQEn80MrpvBJ7AqwlQycVF66DXOS7H0QHyxMb9cgr8MSQEphANnEuEuPhwYPlFqH1zuaezmULMtf5NFuoaRpBdK9JAO7iowYJZrYH8KN5Ii-mbW0WqsQQ/s72-c/Cat%20ANN%20AI.jpg)
![[Guest post] Does ‘ICE LAND’ mislead consumers about the origin of the goods? (Unlike EUIPO) No, says Appeal Board in Uzbekistan](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgPGw8_7E4v_1WEkXXbQcUKDspanjGJ8znukimelJ4kRhwALH5Loirg8pN9sGw84wcoJ2ifRMpxFV8CLUae7tGB8pEb7A3IJku3V8kUJ9oNmOrHfVfEGpGVJI01niLxUgKZ-rllhgTEdXQoZz4Xvbws8yd3Stq3jClMIYBBfQ83ws5ckvnKjHLXwQ/s72-c/Picture%202.jpg)
Posts
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html